ArticlemAbs2016

Targeted immunotherapy using anti-CD138-interferon α fusion proteins and bortezomib results in synergistic protection against multiple myeloma.

Alex Vasuthasawat et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.